Vaxart Statistics
Total Valuation
Vaxart has a market cap or net worth of 118.19 million. The enterprise value is 66.76 million.
| Market Cap | 118.19M |
| Enterprise Value | 66.76M |
Important Dates
The next estimated earnings date is Thursday, November 5, 2026.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Vaxart has 243.20 million shares outstanding. The number of shares has increased by 4.01% in one year.
| Current Share Class | 243.20M |
| Shares Outstanding | 243.20M |
| Shares Change (YoY) | +4.01% |
| Shares Change (QoQ) | -0.01% |
| Owned by Insiders (%) | 1.48% |
| Owned by Institutions (%) | 0.17% |
| Float | 239.61M |
Valuation Ratios
The trailing PE ratio is 3.00.
| PE Ratio | 3.00 |
| Forward PE | n/a |
| PS Ratio | 0.49 |
| PB Ratio | 1.43 |
| P/TBV Ratio | 1.57 |
| P/FCF Ratio | 3.54 |
| P/OCF Ratio | 3.48 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 1.29, with an EV/FCF ratio of 2.00.
| EV / Earnings | 1.73 |
| EV / Sales | 0.27 |
| EV / EBITDA | 1.29 |
| EV / EBIT | 1.69 |
| EV / FCF | 2.00 |
Financial Position
The company has a current ratio of 1.60, with a Debt / Equity ratio of 0.15.
| Current Ratio | 1.60 |
| Quick Ratio | 1.52 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | 0.24 |
| Debt / FCF | 0.38 |
| Interest Coverage | 18.03 |
Financial Efficiency
Return on equity (ROE) is 66.97% and return on invested capital (ROIC) is 102.82%.
| Return on Equity (ROE) | 66.97% |
| Return on Assets (ROA) | 15.04% |
| Return on Invested Capital (ROIC) | 102.82% |
| Return on Capital Employed (ROCE) | 43.02% |
| Weighted Average Cost of Capital (WACC) | 10.78% |
| Revenue Per Employee | 3.74M |
| Profits Per Employee | 593,677 |
| Employee Count | 65 |
| Asset Turnover | 1.48 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Vaxart has paid 419,000 in taxes.
| Income Tax | 419,000 |
| Effective Tax Rate | 1.07% |
Stock Price Statistics
The stock price has increased by +25.26% in the last 52 weeks. The beta is 1.06, so Vaxart's price volatility has been similar to the market average.
| Beta (5Y) | 1.06 |
| 52-Week Price Change | +25.26% |
| 50-Day Moving Average | 0.52 |
| 200-Day Moving Average | 0.58 |
| Relative Strength Index (RSI) | 44.00 |
| Average Volume (20 Days) | 274,500 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 7.74 |
Income Statement
In the last 12 months, Vaxart had revenue of 243.07 million and earned 38.59 million in profits. Earnings per share was 0.16.
| Revenue | 243.07M |
| Gross Profit | 58.80M |
| Operating Income | 39.61M |
| Pretax Income | 39.01M |
| Net Income | 38.59M |
| EBITDA | 45.62M |
| EBIT | 39.61M |
| Earnings Per Share (EPS) | 0.16 |
Balance Sheet
The company has 63.98 million in cash and 12.54 million in debt, with a net cash position of 51.44 million or 0.21 per share.
| Cash & Cash Equivalents | 63.98M |
| Total Debt | 12.54M |
| Net Cash | 51.44M |
| Net Cash Per Share | 0.21 |
| Equity (Book Value) | 82.37M |
| Book Value Per Share | 0.34 |
| Working Capital | 43.58M |
Cash Flow
In the last 12 months, operating cash flow was 33.98 million and capital expenditures -601,000, giving a free cash flow of 33.38 million.
| Operating Cash Flow | 33.98M |
| Capital Expenditures | -601,000 |
| Depreciation & Amortization | 6.00M |
| Net Borrowing | n/a |
| Free Cash Flow | 33.38M |
| FCF Per Share | 0.14 |
Margins
Gross margin is 24.19%, with operating and profit margins of 16.30% and 15.88%.
| Gross Margin | 24.19% |
| Operating Margin | 16.30% |
| Pretax Margin | 16.05% |
| Profit Margin | 15.88% |
| EBITDA Margin | 18.77% |
| EBIT Margin | 16.30% |
| FCF Margin | 13.73% |
Dividends & Yields
Vaxart does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.01% |
| Shareholder Yield | -4.01% |
| Earnings Yield | 32.65% |
| FCF Yield | 28.24% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Vaxart is 3.33, which is 585.19% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 3.33 |
| Price Target Difference | 585.19% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | -51.70% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Vaxart has an Altman Z-Score of -0.52 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.52 |
| Piotroski F-Score | 6 |